Advances in cancer immunity have promoted a major breakthrough in the field of cancer
therapy. This is mainly associated with the successful development of immune checkpoint …

Up to a fifth of patients with colorectal cancer (CRC) present with synchronous hepatic
metastases. In patients with CRC who present without intestinal obstruction or perforation …

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)
for Colon Cancer focuses on systemic therapy options for the treatment of metastatic …

This portion of the NCCN Guidelines for Colon Cancer focuses on the use of systemic
therapy in metastatic disease. Considerations for treatment selection among 32 different …

PURPOSE To provide expert guidance to clinicians and policymakers in resource-
constrained settings on the management of patients with late-stage colorectal cancer …

2.1 Geltungsbereich und Zweck 2.1. 1. Zielsetzung und Fragestellung Das Kolorektale
Karzinom (KRK) ist mit etwa 64 000 Neuerkrankungen und ca. 26 000 Todesfällen pro Jahr …

Background BEVZ92 is a proposed biosimilar to bevacizumab. The two molecules have
similar physicochemical and functional properties in in-vitro and preclinical studies. In this …

Nowadays, colorectal cancer is the fourth most common type of tumor all over the world.
When diagnosed,∼ 50%–60% of tumors have metastasized, thus resulting in a grim …

Background Microsatellite stable (MSS) and RAS-mutant metastatic colorectal cancer
(mCRC) patients are characterized by an immunosuppressive microenvironment and a low …

Background The management of colorectal cancer with synchronous liver-limited
metastases currently lacks randomised trial evidence to inform case selection for any of the …